Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult3. fázis

USTiGA

A legfontosabb adatok

Ki végzi
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Hol
Németország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
70 fő, tervezett
Kezdés
2026. okt. 1.
Várható befejezés
2030. jún. 30.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. október 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people aged 50 or older with active giant cell arteritis (GCA), newly diagnosed or flaring. It tests upadacitinib with a shorter prednisolone course.

Életkor
50 years or older
Nem
Men and women
A betegség stádiuma
Newly diagnosed or flaring GCA, confirmed by imaging or biopsy. The disease must be active but stable enough to start the steroid taper set by the protocol.
Korábbi kezelés
No prednisolone above 5mg/day for more than 7 days before screening. No previous upadacitinib. No other conventional, biologic or targeted synthetic DMARD in the 3 months before joining.
Biomarker vagy leletérték
A history of CRP >= 10 mg/l or ESR >= 50 mm/hour, plus at least one other sign or imaging finding of active GCA.

A részvétel fő kizáró okai

  • Past blood clots in the veins, or a raised clotting risk other than GCA
  • HIV, active TB, hepatitis B or C, or serious or repeated infections
  • Cancer in the past, except treated non-melanoma skin cancer or cervical carcinoma in situ
  • Stroke, heart attack or heart procedures in the past 6 months
  • Pregnant or breastfeeding women

A regiszter feltételei, szó szerint

Mind a 36 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female, aged ≥ 50 years
  • Written informed consent for voluntary participation in the trial
  • Newly diagnosed or flaring GCA as confirmed by a board certified rheu-matologist through imaging or biopsy, further fulfilling the classification criteria for GCA
  • Prior to the screening, trial participant should not receive prednisolone (> 5mg/ day) for more than 7 days for treatment of GCA. The allowed screen-ing period is three days, in which corticosteroid regimen is allowed in an in-itial prednisolone dose of up to 60 mg p.o. q1d (and in case of visual symptoms 250 mg i.v. q1d)
  • Trial participant should be in active disease as assessed by the treating rheumatologist, with a history of CRP >= 10 mg/l or ESR >= 50 mm/hour and at least one additional clinical, or imaging criterion indicative of active GCA. These include new-onset or aggravated headache, jaw claudication, tongue burning, visual impairment, constitutional symptoms, or imaging ev-idence of active vasculitis, in vascular ultrasound, PET/CT or MRI/MRA
  • Trial participant must have GCA that, in the opinion of the investigator, is clinically stable to allow the trial participant to safely initiate the protocol-defined CS taper regimes
  • Willing and able to take upadacitinib with prednisolone or placebo at ran-domization for the entire treatment period
  • Female trial participants agreeing to conduct efficient contraception (unless they have no childbearing potential) during treatment and for four weeks following the final dose of upadacitinib

Ki nem vehet részt

  • Previous treatment with upadacitinib
  • Other active inflammatory rheumatic diseases except concurrent poly-myalgia rheumatica (e.g. rheumatoid arthritis)
  • Current treatment with any other conventional, biologic or targeted syn-thetic DMARD three months prior to study inclusion
  • Contraindications for therapy with upadacitinib or prednisolone, as in-dicated in the product characterics
  • Two or more prior episodes of herpes zoster, or one or more episodes of disseminated herpes zoster
  • One or more prior episodes of disseminated herpes simplex (including eczema herpeticum)
  • Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the Baseline Visit
  • HBV and HCV screening values that meet the following criteria at the most recent testing prior to the first dose of study treatment: o HBV: hepatitis B surface antigen (HBs Ag) positive (+) test; o HCV: detectable HCV ribonucleic acid (RNA) in any subject with an-ti-HCV antibody (HCV Ab); Recent (within past 6 months) cerebrovascular accident, myocardial in-farction, coronary stenting, aorto-coronary bypass surgery, or venous thromboembolism
  • Subjects with systemic use of known strong cytochrome P450 3A (CYP3A) inhibitors or strong CYP3A inducers 30 days prior to study treatment administration
  • Subjects who have received any live vaccine with replicating potential within 30 days prior to the first dose of upadacitinib, or have expected need of vaccination with any live vaccine with replicating potential dur-ing study participation including at least 30 days after the last dose of upadacitinib. Live vaccines that are incapable of replicating are permit-ted
  • Known or persistent abuse of medication, drugs or alcohol/ reported history (within the last 12 months before screening) or persistent abuse of medication, abuse of drugs or alcohol misuse as assessed by the investigator considering participant’s safety and adherence to treat-ment
  • Conditions other than GCA requiring continuous or intermittent treat-ment with oral or parenteral glucocordicoids unless the last exposure to GCs was > two months before screening
  • History of venous thromboembolism (VTE) or other conditions associ-ated with an elevated risk of thrombosis except GCA
  • Human immunodeficiency virus (HIV) infection, defined as confirmed positive anti-HIV antibody (HIV Ab) test or a positive HIV Ab/Ag test
  • Trial participants with a physical or psychiatric condition which at the investigator’s discretion may put the trial participant at risk, may con-found the trial results, or may interfere with the participant’s participa-tion in this clinical trial
  • Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the subject an unsuitable candidate for the study
  • History of an organ transplant which requires continued immunosup-pression
  • History of an allergic reaction or significant sensitivity to constituents of the study drug and/or other products in the same class
  • History of GI perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment
  • Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery (including sleeve gastrectomy); subjects with a history of gastric band-ing/segmentation are not excluded
  • History of malignancy except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix
  • Known allergy/ intolerance against upadicitinib, prednisolone or an in-gredient
  • History of or current clinically significant medical conditions or any other reason that in the opinion of the Investigator would interfere with the subject's participation in this study, would place the subject at risk by participating in the study or would make the subject an unsuitable candidate to receive study drug, also with regard to the European Commission Decision as of 10 March 2023 on measures to minimize risk of serious side effects with Janus kinase inhibitors (EMA/142279/2023)
  • Simultaneous participation in another clinical trial, or participation in a clinical trial taking an investigational product, up to 30 days prior to last IMP intake in that clinical trial; Screening lab values that meet the following criteria at the most recent testing prior to first upadacitinib administration: o Serum aspartate transaminase (AST) > 2 × ULN; o Serum alanine transaminase (ALT) > 2 × ULN; o Estimated glomerular filtration rate (GFR) by simplified 4-variable MDRD formula < 30 mL/min/1.73 m2; o Total white blood cell (WBC) count < 2,500/µL; o Absolute neutrophil count (ANC) < 1,200/µL; o Platelet count < 100,000/µL; o Absolute lymphocyte count < 750/µL; o Hemoglobin < 9 g/dL o Elevation of creatine kinase levels above two times the norm
  • Active TB (as confirmed via CT that is not older than 3 months). In case of a positive Quantiferon test and exclusion of active TB, a prophylac-tic anti-TB treatment should be initiated based on the treating physi-cian’s clinical judgment as soon as possible
  • Trial participants without legal capacity who is unable to understand the nature, scope, significance and consequences of this clinical trial
  • Pregnant or breast feeding women
  • Female subjects of childbearing potential who are not able and/or will-ing to practice at least 1 protocol-specified method of birth control that is highly effective from Study Day 1 through at least 30 days after the last dose of upadacitinib. Female subjects of non-childbearing poten-tial do not need to use birth control

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To assess the efficacy of upadacitinib and shortened prednisolone therapy scheme in achieving sustained remission of GCA

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Randomized, Double-Blind, Phase II Investigator Initiated Trial of Upadacitinib and Short Glucocorticoid Tapering in Giant Cell Arteritis
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. október 2.